N/A N=42 Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
Squamous Cell Carcinoma of the Oropharynx · HPV
Primary: Rate of Recurrence — 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,903 Validation of an Artificial Intelligence-based Algorithm for Skeletal Age Assessment
Bone Age
Primary: Paired Difference of Skeletal Age Estimate — 5.95; 5.36 months — p=0.04
N/A N=82 Comparison of Rainbow INVSENSOR00001 and Control SpHb Disposable Sensor Performance During Hemodilution
Healthy
Primary: Comparison of INVSENSOR00001 and Control SpHb Sensor by ARMS Calculation — 0.9; 0.9 g/dL
Phase 2 N=225 A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
Advanced Non-small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) (Phase I Part) — 0; 0; 2; 0 Participants
Phase 4 N=45 Gabapentin for Postop Pain After SSLF
Pelvic Organ Prolapse
Primary: Pain During Normal Activities (Surgical Pain Scale Item 2) — 1.6; 3.2 units on a scale — p=0.09
Phase 3 N=35 DS-5565 Phase III Study for Renal Impairment in Japanese Subjects
Diabetic Peripheral Neuropathic Pain · Post-herpetic Neuralgia
Primary: Change From Baseline in Average Daily Pain Score (ADPS) at Each Week — -0.14; -0.20; -0.37; -0.50 units on a scale
Phase 2 N=45 MK-3475 as Maintenance Therapy in Extensive Stage SCLC
Extensive Stage Small Cell Lung Carcinoma
Primary: PFS Using RECIST 1.1 — 1.4 months
Phase 3 N=661 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)
Mesothelioma · Lung Cancer
Primary: Overall Survival (OS) — 30.7; 27.1 Weeks — p=0.858
Phase 2 N=10 A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Teratoma
Primary: Progression Free Survival (PFS) — 71.4; 0.0 Days
N/A N=64 The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
Wilson Disease
Primary: Percentage Of Participants Who Achieved Or Maintained Normalized Concentrations Of Non-ceruloplasmin-bound Copper (NCC) Or Reached A Reduction Of ≥ 25% In NCC During 6…
N/A N=25 Non-Invasive Reduction of Fat in the Flanks of Patients With Sharp Body Curvature
Body Fat Disorder
Primary: Safety of the Zeltiq System for Non-invasive Fat Reduction in Subjects With Greater Flank Curvature. — 0; 0 UADEs
N/A N=33 Neuroimaging in Patients Undergoing TMS for Depression
Treatment Resistant Depression
Primary: Change in Functional Connectivity Measured by Resting MRI — 0.103399365; -0.7637409 correlation coefficients
Phase 3 N=36 Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
Prurigo Nodularis · Nodularis Prurigo · Prurigo
Primary: Overall Incidence and Nature of Treatment Emergent Adverse Events (TEAEs) — 34 Participants
Phase 2 N=241 A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Open-angle Glaucoma, Ocular Hypertension
Primary: Intraocular Pressure in the Study Eye at Month 3 — 18.8; 18.1; 19.7; 19.2 mmHg
Phase 1 N=95 Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults
Respiratory Syncytial Virus
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of the First Product Administration of DS-Cav1 Alone or With Alum Adjuvant — 6; 5; 11…